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Abstract
Background: Spina bifida is a malformation of the neural tube and is the most common of neural tube defects
(NTDs). The etiology of spina bifida is largely unknown, although it is thought to be multi-factorial, involving
multiple interacting genes and environmental factors. Mutations in transcriptional co-activator genes-Cited2, p300,
Cbp, Tfap2a, Carm1 and Cart1 result in NTDs in murine models, thus prompt us to investigate whether
homologues of these genes are associated with NTDs in humans.
Methods: Data and biological samples from 297 spina bifida cases and 300 controls were derived from a
population-based case-control study conducted in California. 37 SNPs within CITED2, EP300, CREBBP, TFAP2A, CARM1
and ALX1 were genotyped using an ABI SNPlex assay. Odds ratios and 95% confidence intervals were calculated for
alleles, genotypes and haplotypes to evaluate the risk for spina bifida.
Results: Several SNPs showed increased or decreased risk, including CITED2 rs1131431 (OR = 5.32, 1.04~27.30),
EP300 rs4820428 (OR = 1.30, 1.01~1.67), EP300 rs4820429 (OR = 0.50, 0.26~0.50, in whites, OR = 0.7, 0.49~0.99 in all
subjects), EP300 rs17002284 (OR = 0.43, 0.22~0.84), TFAP2A rs3798691 (OR = 1.78, 1.13~2.87 in Hispanics), CREBBP
rs129986 (OR = 0.27, 0.11~0.69), CARM1 rs17616105 (OR = 0.41, 0.22~0.72 in whites). In addition, one haplotype
block in EP300 and one in TFAP2A appeared to be associated with increased risk.
Conclusions: Modest associations were observed in CITED2, EP300, CREBBP, TFAP2A and CARM1 but not ALX1.
However, these modest associations were not statistically significant after correction for multiple comparisons.
Searching for potential functional variants and rare causal mutations is warranted in these genes.
Background
Studies using genetically modified mouse models have
contributed a great deal to our understanding of molecu-
lar mechanisms that govern critical embryonic develop-
ment processes, such as neural tube closure. Among the
over 200 existing mouse models for neural tube defects
(NTDs), several harbor mutations in genes encoding
transcriptional activators or co-activators, such as Cited2,
Crebbp, p300, Tfap2a, Carm1 and Cart1 [1-9].
CREB binding protein (CREBBP; CBP) was originally
identified as a protein that binds to the phosphorylated
form of the CREB transcription factor and increases the
expression of genes containing CRE elements. It is clo-
sely related to the adenovirus E1A-associated protein
p300. CBP and p300 are functionally redundant histone
deacetylases essential for proliferation and embryonic
development [5,8,10]. Both Crebbp and p300 genes are
expressed at high level in the neural folds at embryonic
day E8.5 in mice [3]. Homozygous deletions of either
the Crebbp or p300 genes in mice results in lethality on
E9~11, with subsequent defects in neurulation, cell pro-
liferation and cardiac development [5,8].
The methylation of the Crebbp/p300 complex is cata-
lyzed by co-activator-associated arginine methyltransferase
(CARM1). This process disables the recruitment of cAMP
response element binding protein (CREB). Thus, CARM1
functions as a co-repressor in the cAMP signaling
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pathway, via its methyltransferase activity [11]. In addition
to its enzymatic function, CARM1 is also required for NF-
kappaB-dependent gene expression as a transcriptional
cofactor [12]. Carm1 gene expression was observed in the
fore- and hindbrain, neural folds, somites and posterior
lateral plates of E8.25 mouse embryos, and later on in
development (E8.75) expression became prominent in the
neural tube and somites [13].
CITED2 is a nuclear co-activator that binds to CBP/
p300. Disruption of the Cited2 gene in mice is embryonic
lethal, with the mice dying secondary to significant
defects in the development of the neural tube and the
heart [2,6,14,15]. The interaction of CBP and p300 with
Cited2 is required for activation of important transcrip-
tional factors such as AP-2a [1,16]. Mice carrying homo-
zygous disruptions of the gene coding for the protein
AP-2 a (Tfap2 a) die at term as a result of severe devel-
opmental abnormalities. The earliest defect observed was
a complete failure of neural tube closure in the cranial
region, and it has been suggested in a chimera model
study that there is an independent requirement for AP-2
a in the formation of the neural tube [17-19].
CART1 is a paired-class homeobox-containing tran-
scription factor regulated by CBP/p300 acetylation of a
highly conserved lysine residue that increases the interac-
tion between CBP/p300 and CART1, ultimately enhancing
its transcriptional activation [20]. The Cart1 gene is
expressed in chondrocytes [21,22], and appears to be
required for embryonic forebrain mesenchymal survival.
The absence of CART1 disrupts cranial neural tube
morphogenesis by blocking the initiation of closure in the
midbrain region. Homozygous Cart1 mutant mice are
born alive with neural tube closure defects including
acrania and meroanencephaly, but die soon after birth [9].
The Cart1 knockout mouse is among several NTD mouse
models that can be rescued by maternal supplementation
with folic acid [23]. The gene encoding human CART1
is ALX1 (ALX homobox 1). In summary, CBP, p300,
CARM1, TFAP2a, CITED2 and CART1 are transcrip-
tional activator/co-activators that contributes to the onto-
geny of the neural tube in mammalian systems. Whether
gene homologues are associated with human NTDs
remains unknown. Three single nucleotide polymorphisms
(SNP) in the un-translated region of CITED2 gene were
studied in a group of patients with spina bifida and con-
trols, modest associations were observed but results were
imprecise owing to small sample size [14]. Mutations in
the human CBP gene have been identified as being respon-
sible for the Rubinstein-Taybi syndrome (RTS), which has
a defined craniofacial phenotype [4]. The purpose of this
study is to evaluate the potential association between var-
iations among human CITED2, CREBBP, EP300, TFAP2A,
CARM1 and ALX1 genes and the risk for spina bifida.
Methods
Study Population
Data and biological samples were obtained from a case-
control study conducted by the California Birth Defects
Monitoring Program (CBDMP). The CBDMP is an active,
population-based surveillance system for collecting infor-
mation on infants and fetuses with structural congenital
malformations, which has been described elsewhere [24].
Included were 297 singleton infants with spina bifida
(cases) and 300 non-malformed infants (controls). Both
cases and controls were randomly selected from the
samples with bloodspots available. Cases were selected
from California Birth Defect Registry 1990-1999; non-
malformed controls were selected from Vital Statistics
matching the birth years with the selected cases. Case and
control infants were linked to their newborn screening
bloodspots. All samples were obtained with approval from
the State of California Health and Welfare Agency
Committee for the Protection of Human Subjects.
Candidate genes and SNPs
The 6 candidate genes and SNPs genotyped are listed in
Table 1. Tagging SNPs were selected for each candidate
gene using the SNPbrowser™ Software (ABI, Foster City,
CA) based on data from the four HapMap populations
(CEU, YRI, JPT and CHB) [25]. All validated tagging
SNPs with pairwise r2 > = 0.8 with a minor allele fre-
quency (MAF) no less than 5% were included for geno-
typing. Also included for study were all non-synonymous
coding SNPs in these genes. Based on these criteria, 37
SNPs were genotyped.
Genotyping Approach
DNA was extracted from blood spots using the Gentra
Puregene DNA Extraction Kit (Qiagen, Valencia, CA)
following the standard protocol. Prior to genotyping,
genomic DNA was amplified using a commercially avail-
able multiple displacement amplification (MDA) kit,
GenomiPhi DNA Amplification kit (GE Healthcare, Pis-
cataway, NJ). The whole genome amplification (WGA)
product was then quantified using RNase P assay
(AppliedBiosystems, Foster City, CA). 200 ng of WGA
product was used for the SNPlex assay containing the
37 SNPs. All genotyping assays were performed blinded
to subjects’ case or control status.
The SNPs selected for analyses were submitted to
Applied Biosystems to create a unique SNPlex assay.
The SNPlex™ genotyping system (Applied Biosystems,
Foster City, CA) is based on a universal multiplexed oli-
gonucleotide ligation assay (OLA)/PCR and drag chute
mobility modifier technology. The resulting genotype
data were analyzed using GeneMapper™ v4.0 (Applied
Biosystems, Foster City, CA).
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Analytic procedures
Analyses were performed for the overall study group as
well as for specific ethnic/race groups. Hispanic infants
were further subdivided into those whose mothers were
born in the United States, or native-born (Hisp-NB) and
those whose mothers were not, or foreign-born (Hisp-FB),
as it has been shown that these two groups are different
with respect to ethnic composition and social economic
Table 1 Characteristics of all genotyped SNPs
Gene
(Alias)
Marker Chromosome Chromosome
position
RefSNP
alleles
Call
Rate
(%)
MAF*
(All
subjects)
HWE P
(controls)
MAF
(White)
HWE** P
(White
controls)
MAF
(Hispanic)
HWE P
(Hispanic
controls)
ALX1
(CART1)
rs11608773 12 84229006 A/G 100.0 0.229 0.435 0.274 0.478 0.217 0.391
rs4761130 12 84226396 C/T 99.8 0.421 0.286 0.358 0.154 0.401 0.465
rs7295242 12 84222948 A/G 100.0 0.161 0.781 0.074 0.557 0.159 0.358
CARM1 rs11667234 19 10880581 A/C 99.8 0.021 0.010 0.039 0.071 0.016 0.934
rs11670365 19 10865833 C/T 100.0 0.056 0.918 0.084 0.754 0.045 0.702
rs1529711 19 10884434 A/G 99.7 0.097 0.492 0.161 0.932 0.081 0.519
rs1541596 19 10848013 A/G 99.5 0.475 0.326 0.497 0.969 0.408 0.957
rs17616105 19 10883159 C/T 100.0 0.189 0.732 0.235 0.365 0.152 0.072
rs7254708 19 10863579 A/G 100.0 0.071 0.043 0.123 0.116 0.059 0.441
CITED2 rs1131431 6 139735527 A/G 100.0 0.153 0.273 0.200 0.624 0.121 0.948
rs7775752 6 139737486 A/G 45.1 0.007 0.957 0.009 0.913 0.006 1.000
CREBBP
(CBP)
rs11076783 16 3722706 C/T 100.0 0.154 0.638 0.116 0.142 0.139 0.802
rs11076785 16 3730187 G/T 46.6 0.457 0.638 0.401 0.185 0.457 0.463
rs11076786 16 3751597 C/T 100.0 0.075 0.008 0.077 0.441 0.046 0.637
rs129986 16 3744242 C/T 100.0 0.023 0.530 0.032 0.590 0.020 0.735
rs130003 16 3768173 A/G 99.8 0.015 0.792 0.032 0.711 0.010 0.967
rs130008 16 3721953 C/G 99.8 0.011 0.838 0.032 0.752 0.001 1.000
rs17136507 16 3740546 C/T 100.0 0.178 0.536 0.110 0.229 0.227 0.449
rs886528 16 3751557 C/T 99.7 0.383 0.590 0.390 0.986 0.368 0.839
rs9392 16 3715170 A/G 99.8 0.189 0.566 0.223 0.625 0.138 0.700
EP300
(P300)
rs17002284 22 39826792 A/G 100.0 0.265 0.220 0.313 0.745 0.217 0.522
rs17433014 22 39829768 A/G 99.8 0.018 0.769 0.029 0.793 0.019 0.834
rs2230111 22 39851949 A/G 99.8 0.002 0.977 0.006 0.959 1.000 1.000
rs4820428 22 39867535 A/G 100.0 0.446 0.006 0.329 0.822 0.419 0.667
rs4820429 22 39868057 C/G 100.0 0.159 0.382 0.258 0.040 0.124 0.471
rs4822006 22 39849308 C/T 100.0 0.247 0.844 0.355 0.587 0.185 0.740
rs5758246 22 39871792 A/G 100.0 0.030 0.635 1.000 1.000 0.012 0.934
rs9611502 22 39861182 C/T 100.0 0.014 0.838 0.019 0.918 0.013 0.867
TFAP2A
(AP2)
rs10456013 6 10506548 G/T 100.0 0.032 0.592 0.048 0.670 0.026 0.735
rs1621700 6 10528084 A/G 99.7 0.288 0.671 0.252 0.081 0.357 0.773
rs303050 6 10511169 C/T 100.0 0.257 0.061 0.165 0.259 0.262 0.267
rs303055 6 10527462 C/T 100.0 0.353 0.150 0.435 0.569 0.335 0.025
rs303056 6 10528467 C/G 100.0 0.159 0.229 0.094 0.477 0.126 1.000
rs3798691 6 10519381 C/G 100.0 0.112 0.021 0.042 0.011 0.134 0.111
rs3798694 6 10516743 A/G 100.0 0.062 0.122 0.087 0.225 0.059 0.293
rs533558 6 10503558 A/G 100.0 0.441 0.848 0.361 0.955 0.481 0.858
rs537112 6 10503192 A/G 100.0 0.180 0.571 0.103 0.754 0.195 0.255
*MAF: minor allele frequency; **HWE: Hardy-Weinberg Disequilibrium.
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status [26,27]. Departure from Hardy-Weinberg Equili-
brium (HWE) was assessed by Chi-square analysis in each
subgroup using data from controls only. Odds ratios (OR)
for SNP genotypes were calculated using logistic regres-
sion analyses. Since the mode of inheritance is unknown,
potential associations with spina bifida risk were evalua-
ted assuming dominant, recessive and additive models
for each SNP. Chi-square tests were used to assess the sig-
nificance of dominant and recessive models. Cochran-
Armitage trend tests were used to assess the significance
of additive models. If numbers were less than 5, Fisher’s
exact test and Exact Armitage trend test were applied.
Analyses were performed using SVS v7.1.1 (GoldenHelix,
Bozeman, MT) software. The false discovery rate (FDR)
[28] was used to account for multiple testing (data
not shown). Haplotype blocks were constructed using
HaploView 4.2 http://www.broadinstitute.org/haploview/
haploview in each race/ethnicity group with pair-wise
D’≥0.85. Haplotype frequencies were estimated based on
the Maximum Expectation (EM) algorithm. Association of
each haplotype was evaluated by calculating ORs and 95%
confidence intervals against all other haplotypes. Estimated
risks were considered statistically precise if 95% confiden-
tial interval of OR does not include 1.00.
Results and Discussion
Demographic characteristics of the cases and controls
are listed in Table 2. Cases and controls were similar
with respect to maternal age, parity, and plurality but
expectedly differed with respect to race/ethnicity and
maternal educational attainment. That is, the data
revealed greater frequencies of Hispanics (primarily for-
eign born) and women with low educational level (less
than high school) in the spina bifida case group.
Genotyping of 37 SNPs was performed using a custom-
made Applied Biosystems SNPlex panel. Due to low call
rates, two SNPs, rs7775752 (45.1%) and rs11076785
(46.6%), were excluded from analysis. Departure
from HWE in the controls (p < 0.01) was observed in
rs11076786 and rs4820428 when analyzing the whole
dataset. This deviation was eliminated when stratified by
race/ethnicity (Table 1). Several SNPs and haplotypes con-
taining these SNPs showed modest associations with spina
bifida risk (p ≤ 0.05, Table 3 and 4). These associations are
summarized below for each gene. The results, however,
are largely indicative of no or very limited associations,
particularly after correction for multiple comparisons.
CITED2
Only one of the two SNPs genotyped was fully analyzed.
SNP rs1131431 showed a genotypic association (OR =
5.32, 95% CI: 1.04~27.30) based on a recessive mode of
inheritance, specifically in the White population. It is
noteworthy that the confidence interval had a wide
range, suggesting that the estimate may be imprecise
due to the small number of White cases and controls
with the variant. This SNP, however, was previously
associated with a modest increase in risk for spina bifida
and congenital heart defects [14].
EP300
Among the 8 SNPs analyzed, the G allele of SNP
rs4820428 was over-represented in spina bifida cases
(OR = 1.30, 95% CI: 1.01~1.67) in all subjects. Analyses
showed that rs4820428 was associated with spina bifida
risk under a dominant model (OR = 1.54 95%CI:
1.10~2.17). The minor allele of rs4820429 (C) showed a
reduced risk in the Whites (OR = 0.50, 95% CI:
0.26~0.50) and in the whole dataset (OR = 0.70, 95% CI:
0.49~0.99) under a dominant model. Minor allele of
rs17002284 (G) also showed a reduced risk (OR = 0.43,
95%CI: 0.22~0.84), but under a recessive model. These
three SNPs were in linkage disequilibrium. Subsequent
analysis showed that haplotype ACGG (rs17002284-
rs4822006-rs4820428-rs4820429) accounted for 50.3% of
Table 2 Demographic distribution of malformed cases
and non-malformed controls, California 1990-1999
Variable Spina Bifida
Cases
n = 297 (%1)
Controls
n = 300 (%1)
Maternal Race/Ethnicity
White, non-Hispanic 59 (19.9) 96 (32.0)
Hispanic, Native Born 33 (11.1) 33 (11.0)
Hispanic, Foreign Born 166 (55.9) 115 (38.3)
Black 17 (5.7) 20 (6.7)
Asian 9 (3.0) 25 (8.3)
Other 9 (3.0) 11 (3.7)
Maternal age at delivery (years)
13-24 128 (43.1) 123 (41.0)
25-29 80 (26.9) 71 (23.7)
30-34 47 (15.8) 64 (21.3)
35-55 39 (13.1) 42 (14.0)
Maternal education
Less than high school 158 (53.2) 110 (36.7)
High School 65 (21.9) 81 (27.0)
Greater than High school 71 (23.9) 109 (36.3)
Parity
0 120 (40.4) 114 (38.0)
1 88 (29.6) 101 (33.7)
≥2 86 (29.0) 84 (28.0)
Plurality
Singleton 287 (96.6) 293 (97.7)
Multiple births 8 (2.7) 7 (2.3)
Infant Sex
Male 146 (49.2) 149 (49.7)
Female 151 (50.8) 151 (50.3)
1Percentages may not equal 100 owing to missing data or rounding.
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all haplotypes in the Whites and was over-represented
in the white cases (OR = 1.30, 95%CI: 1.01~1.67). It is
noteworthy that this high risk haplotype contains the
high risk alleles for rs17002284 (A), rs4820428 (G) as
well as rs4820429 (G) (Table 5).
TFAP2
Among the 9 SNPs analyzed, rs303056 (C), rs3798691
(C), rs533558 (G) showed allelic association with spina
bifida risk in Hispanics. Genotypic association analysis
showed that rs3798691 was associated with spina bifida
risk under a dominant model in Hispanics (OR = 1.78,
95% CI: 1.13~2.87). SNP rs533558 also showed an asso-
ciation under a dominant model, but only in native-born
Hispanics (OR = 3.32, 95%CI: 1.08~10.18). Subsequent
haplotype analysis predicted two haplotype blocks in
Hispanics. Haplotype AGCGC of block1 (rs537112-
rs533558-rs303050-rs3798694-rs3798691) had an average
Table 3 Allele associations (P < 0.05) among subgroups
SNP Gene Ethnicity refSNP alleles Minor Allele Ratio Counts
(Case, Control)
P value Odds Ratio 95% CI
rs129986 CREBBP (CBP) white C/T T 118:0, 182:10 0.008* n/a n/a
rs17616105 CARM1 white C/T C 101:17, 136:56 0.003 2.45 1.34-4.46
rs303056 TFAP2A (AP2) white C/G C 16:102, 13:179 0.046 2.16 1.00-2.15
rs3798691 TFAP2A (AP2) Hispanic C/G C 65:333, 29:267 0.013 1.80 1.13-2.87
Hispanic-FB C/G C 52:280, 22:208 0.036 1.76 1.03-2.98
rs533558 TFAP2A (AP2) Hispanic-NB A/G G 36:30, 24:42 0.036 2.10 1.05-4.22
rs4820428 EP300 (P300) All subjects A/G G 276:240, 229:259 0.038 1.30 1.01-1.67
Table 4 Genotype associations (P < 0.05) among subgroups under different modes of inheritance
Marker Gene Ethnicity P value Mode of Inheritance Odds Ratio
[(ratio count (case, control))
95% CI
rs17002284 EP300 All subjects 0.012 Recessive 0.43 (13, 29; 284, 271) 0.22 - 0.84
rs4820428 EP300 All subjects 0.011 Additive [(Dd) vs (dd)] 1.46 (132, 122; 87, 117) 1.00 - 2.11
[(DD) vs (Dd)] 1.18 (78, 61; 132, 122) 0.78 - 1.79
All subjects 0.012 Dominant 1.54 (210, 183; 87, 117) 1.10 - 2.17
rs4820429 EP300 All subjects 0.046 Dominant 0.70 (75, 98; 222, 202) 0.49 - 0.99
White 0.041 Dominant 0.50 (22, 52; 37, 44) 0.26 - 0.50
rs1621700 TFAP2A All subjects 0.041 Additive [(Dd) vs (dd)] 1.30 (131, 118; 138, 161) 0.92 - 1.81
[(DD) vs (Dd)] 1.33 (28, 19; 131, 118) 0.70 - 2.50
rs3798691 TFAP2A Hispanic 0.015 Additive [(Dd) vs (dd)] 1.78 (48, 23; 143, 122) 1.04 - 3.19
[(DD) vs (Dd)] 1.40 (9, 3; 47, 22) 0.35 - 5.70
Hispanic 0.022 Dominant 1.84 (56, 26; 143, 122) 1.13 - 3.25
Hispanic-FB 0.049 Dominant 1.82 (44, 19; 122, 92) 1.00 - 3.40
rs533558 TFAP2A Hispanic-NB 0.038 Additive [(Dd) vs (dd)] 3.00 (18, 14; 6, 14) 0.92 - 9.80
[(DD) vs (Dd)] 1.40 (9, 5; 18, 14) 0.38 - 5.12
Hispanic-NB 0.032 Dominant 3.32 (27, 19; 6, 14) 1.08 - 10.18
rs17616105 CARM1 Hispanic 0.0 Recessive n/a (6, 0; 193, 148) n/a
White 0.004 Additive [(Dd) vs (dd)] 0.48 (15, 36; 43,50) 0.23 - 1.00
[(DD) vs (Dd)] 0.24 (1,10; 15,36) 0.03 - 2.04
White 0.010 Dominant 0.40 (16, 46; 43, 50) 0.40 - 0.20
rs1131431 CITED2 White 0.027 Recessive 5.32 (6, 2; 53, 94) 1.04 - 27.30
rs129986 CREBBP All subjects 0.005 Additive [(Dd) vs (dd)] 0.27 (6, 21; 291, 279) 0.11 - 0.69
[(DD) vs (Dd)] n/a (0, 0; 6, 21) n/a
All subjects 0.003 Dominant 0.27 (6, 21; 291, 279) 0.11 - 0.69
White 0.014 Additive [(Dd) vs (dd)] n/a (0, 10; 59, 86) n/a
[(DD) vs (Dd)] n/a (0, 0; 0, 10) n/a
White 0.010 Dominant n/a (0, 10; 59, 86) n/a
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frequency of 0.133 and was associated with an increased
risk, OR = 1.73 (1.08-2.77) compared to all other haplo-
types. Since no high risk SNP has been discovered, these
high risk blocks will be thoroughly sequenced to search
for other variants (Table 5).
CREBBP
Among the 8 SNPs analyzed, the heterozygous status of
SNP rs129986 (TC) was associated with a reduced risk
in all subjects (OR = 0.27, 95% CI: 0.11~0.69). The
homozygous status of the minor allele, CC, was not
observed. The TC genotype was observed in only 6
cases and they were all Hispanics.
CARM1
6 SNPs were genotyped. In Whites, the minor allele (C) of
rs17616105 showed a reduced risk with OR = 0.41 (95%
CI: 0.22~0.75). Genotype analysis showed that this effect
followed a dominant inheritance model (ORCC+CT = 0.40,
95% CI: 0.20~0.40), and was not observed in the
Hispanics.
ALX1
3 SNPs were genotyped. No association was observed
between any SNP and spina bifida risk. It is known that
the Cart1 knockout mouse responses to maternal supple-
mentation with folic acid [23]. The majority of the DNA
samples for this study were collected after folic acid forti-
fication is implied in the USA, which might interact with
the genotyping effect; however, our study lacks the statis-
tic power to analyze the gene-environment interaction.
To our knowledge, this is the first study evaluating
human CREBBP, EP300, CARM1, TFAP2A, and ALX1
genes as possible risk factors for spina bifida. Associa-
tion between CITED2 and spina bifida has been studied
before, and results from our current study are consistent
with the previous findings [14]. Modest associations
were observed between spina bifida risk and TFAP2A,
EP300, CITED2, CREBBP1 and CARM1. No association
was observed in ALX1 gene. However, given the number
of comparisons made, relatively few associations
emerged. Although NTDs are multifactorial diseases, it
cannot be excluded that the studied genes may contain
rare mutations that cause some of the NTDs. With the
most advanced next-generation sequencing technique
being available, we may be able to discover such rare
variants in our study population.
The strengths of this study include its population-
based ascertainment of cases and controls and its eva-
luation of race/ethnicity as potential modifiers of risk in
the presence of variant genotypes and haplotypes. A
major limitation of our study was the small sample size,
which reduced the statistical power of analyses. Replica-
tion of some of the modest findings in a larger sample
set may be warranted.
Conclusions
We have observed modest associations with risk of spina
bifida in CITED2, EP300, CREBBP, TFAP2A and CARM1
genes but not ALX1 gene. These modest associations
were not statistically significant after correction for mul-
tiple comparisons. Future effort will focus on searching
for potential functional variants and rare causal muta-
tions in these potential candidate genes.
Abbreviations
CREB: cAMP response element binding protein; CRE: cyclic AMP-responsive;
CITED2: Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-
terminal domain, 2; EP300: E1A binding protein p300 (Alias: p300); CREBBP:
CREB binding protein (Alias: CBP); TFAP2A: transcription factor AP-2 alpha
(activating enhancer binding protein 2 alpha) (Alias: AP-2); CARM1:
coactivator-associated arginine methyltransferase 1; ALX1: ALX homeobox 1
(Alias: CART1).
Table 5 Haplotype associations (only significant associations are shown)
Haplotype Block Frequency P Value Odds Ratio (case, control) 95% CI
TFAP2A-rs537112, rs533558, rs303050, rs3798694, and rs3798691 in Hispanic
AGCGC 0.133 0.0205 1.73 (63.0 : 335.0, 29.0 : 267.0) 1.08-2.77
GATGG 0.516 0.2019 0.82 (197.0 : 201.0, 161.0 : 135.0) 0.61-1.11
GGTGG 0.201 0.8135 0.96 (78.9 : 319.1, 60.8 : 235.2) 0.66-1.39
GGCAG 0.058 0.4974 1.26 (25.0 : 373.0, 15.0 : 281.0) 0.65-2.43
AGCGG 0.041 0.3207 0.69 (13.9 : 384.1, 14.8 : 281.2) 0.33-1.45
GGCGG 0.028 0.6568 0.81 (10.1 : 387.9, 9.2 : 286.8) 0.33-2.00
AGTGG 0.021 0.9639 0.97 (8.1 : 389.9, 6.2 : 289.8) 0.34-2.79
EP300- rs17002284, rs4822006, rs4820428 and rs4820429 in non-Hispanic white
ACGG 0.503 0.0377 1.30 (276.0 : 240.0, 229.0 : 259.0) 1.01-1.67
GCAG 0.245 0.1665 0.82 (117.0 : 399.0, 129.0 : 359.0) 0.61-1.09
ATAC 0.163 0.054 0.72 (73.0 : 443.0, 91.0 : 397.0) 0.51-1.00
ATAG 0.072 0.8074 1.06 (38.0 : 478.0, 34.0 : 454.0) 0.66-1.72
ACAG 0.015 0.2348 1.91 (10.0 : 506.0, 5.0 : 483.0) 0.65-5.63
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